Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 3,023 matching trials from the live ClinicalTrials.gov search.
Conditions
Sarcoma
Interventions
dactinomycin, filgrastim, pegfilgrastim, sargramostim, cyclophosphamide, irinotecan hydrochloride, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 49 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
209
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Conditions
Melanoma
Interventions
Ipilimumab, Melphalan and Dactinomycin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
New York, New York
Conditions
Cancer of Head and Neck, Cancer of Cervix, Cancer of Anus
Interventions
DPX-E7 vaccine, Cyclophosphamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Colon Cancer, Resected Stage
Interventions
Cetuximab, Expanded CB-NK cells, Fludarabine phosphate, Cyclophosphamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Renal Cell Cancer
Interventions
Fludarabine, Melphalan, Cyclophosphamide, Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Houston, Texas
Conditions
Brain and Central Nervous System Tumors
Interventions
cisplatin, etoposide, ifosfamide, lomustine, methotrexate, prednisone, vincristine sulfate
Drug
Lead sponsor
German Society for Pediatric Oncology and Hematology GPOH gGmbH
Other
Eligibility
3 Years to 18 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Houston, Texas
Conditions
Metastatic Melanoma
Interventions
Ipilimumab, Tumor Infiltrating Lymphocytes (TIL), Administration of Lymphodepletion, Cyclophosphamide as Part of Lymphodepletion, Fludarabine as Part of Lymphodepletion, High Dose IL-2, Adoptive Cell Therapy with TIL
Drug · Procedure · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Breast Cancer
Interventions
filgrastim, cyclophosphamide, paclitaxel, thiotepa, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
Up to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Hematologic and Lymphocytic Disorder
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide, Fludarabine, Itacitinib, Tacrolimus, Thiotepa
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Lymphocytic Leukemia, Chronic
Interventions
obinutuzumab, rituximab, chlorambucil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
5
States / cities
San Diego, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Conditions
Solid Tumors
Interventions
Kareniticin and cyclophosphamide
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Months to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Conditions
Multiple Myeloma
Interventions
lenalidomide, melphalan
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Neuroblastoma, Bone Marrow, Sympathetic Nervous System
Interventions
cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
New York, New York
Terminated Phase 2 Interventional Results available

Post Transplant Donor Lymphocyte Infusion

NCT00167180
Conditions
Leukemia, Myeloid, Chronic, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, Leukemia, Lymphocytic, Acute, Leukemia, Lymphocytic, Chronic, AML
Interventions
Donor Lymphocyte Infusion, Induction Chemotherapy
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
1 Year to 70 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, melphalan
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
New York, New York
Conditions
Leukemia
Interventions
cyclophosphamide, methotrexate, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, iodine I 131 monoclonal antibody BC8, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
2 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Pancreatic Cancer
Interventions
Cyclophosphamide, GVAX Pancreatic Cancer Vaccine, Pembrolizumab, SBRT
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT

NCT03018223
Conditions
Non-Hodgkin's Lymphoma, Acute Leukemia in Remission, Chronic Myeloid Leukemia, Primary Myelofibrosis, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Hodgkin Lymphoma, Multiple Myeloma
Interventions
Fludarabine, Busulfan, Cyclophosphamide, Total body irradiation (TBI), Peripheral Blood Hematopoietic Cell Transplantation (HCT), Sirolimus (SIR), Mycophenolate mofetil (MMF), Granulocyte-colony stimulating factor (G-CSF)
Drug · Radiation · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Chronic Lymphocytic Leukemia
Interventions
IPI-145, Fludarabine, Cyclophosphamide, Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Docetaxel, Paclitaxel
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
4,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
914
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 612 more
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Busulfan, Cyclophosphamide, Echocardiography Test, Fludarabine, Haploidentical Hematopoietic Cell Transplantation, Lapine T-Lymphocyte Immune Globulin, Lumbar Puncture, Matched Unrelated Donor Hematopoietic Cell Transplantation, Melphalan, Methotrexate, Multigated Acquisition Scan, Mycophenolate Mofetil, Myeloablative Conditioning, Quality-of-Life Assessment, Questionnaire Administration, Rituximab, T-Cell Depletion Therapy, Tacrolimus, Thiotepa, Total-Body Irradiation
Procedure · Drug · Biological + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 49 more
Conditions
Ovarian Cancer, Primary Peritoneal Cancer
Interventions
DCVax-L and T Cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Cancer, Breast Neoplasm, Breast Cancer Female, Breast Cancer Invasive, Breast Cancer Stage II, Breast Cancer Stage III, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Neoplasms, Estrogen Receptor-positive Breast Cancer
Interventions
Paclitaxel, Carboplatin, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Pembrolizumab, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Houston, Texas
Conditions
Pancreatic Cancer
Interventions
allogeneic tumor cell vaccine, recombinant interferon alfa, sargramostim, cyclophosphamide
Biological · Drug
Lead sponsor
St. Vincent Medical Center - Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Los Angeles, California